BMS 986497
Alternative Names: BMS-986497; ORM-6151Latest Information Update: 12 Jun 2024
At a glance
- Originator Orum Therapeutics
- Developer Bristol-Myers Squibb; Orum Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Peptide-chain-release factor 3 degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
- Preclinical Haematological malignancies
Most Recent Events
- 12 Jun 2024 Phase-I clinical trials in Acute myeloid leukaemia (Parenteral), prior to June 2024 (Bristol-Myers Squibb pipeline, June 2024)
- 29 May 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in Canada, USA (Parenteral) (NCT06419634)
- 29 May 2024 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in Canada, USA (Parenteral) (NCT06419634)